New York, June 30, 2026, 12:04 (EDT)
- Creative Medical Technology Holdings, Inc. NASDAQ:CELZ surged 252% late morning. The company pulled its June 25 S-1 filing and said no securities were sold under the withdrawn statement.
- Turnover jumped to 146.1 million shares—almost 40 times the 3.70 million shares outstanding in the withdrawn filing.
- The pulled offering would have included as many as 3.05 million common shares along with warrants for 6.09 million additional shares. Warrants already outstanding stayed at roughly 6.10 million shares.
- Biotech ETFs hardly budged, with SPDR S&P Biotech ETF (NYSEARCA:XBI) and iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) both up roughly 0.5%.
Creative Medical Technology Holdings, Inc. NASDAQ:CELZ shares surged Tuesday on Nasdaq. The Phoenix biotech pulled an equity-and-warrant registration statement that was big versus its share count.
Timing is key here. New York was in regular trading hours at the dateline. Nasdaq’s standard U.S. market hours are 9:30 a.m. to 4:00 p.m. ET. Its 2026 holiday calendar points to July 3 as the next market holiday, not June 30.
CELZ last changed hands at $2.85, a surge of $2.0398 over its previous close of around 81 cents. Shares traded between $0.8101 and $4.62. Volume hit 146.1 million shares. Market cap was about $10.5 million.
| Trading read | CELZ | Why investors care |
|---|---|---|
| Price move | Up around 252% | Bounced sharply after closing below $1 on Monday |
| Volume | 146.1 million shares | Roughly 39.5x the S-1/A share count |
| Day range | $0.8101-$4.62 | Hit above the $2.86 warrant strike in the filing |
| XBI / IBB move | Near 0.5% gains in both | Sector didn’t move enough to explain CELZ’s jump |
Creative Medical’s CEO Timothy Warbington pulled the S-1, filing a Rule 477 withdrawal saying the company “no longer plans to consummate the offering.” The S-1 was never declared effective. No shares were issued or sold, the company said. SEC
The S-1/A filing laid it out. The company reported 3,696,668 shares outstanding and said it may offer as many as 3,045,685 new shares at $1.97 each. The deal would also include public warrants linked to another 6,091,371 shares.
| Financing item from S-1/A | Size | Approx. size vs existing shares |
|---|---|---|
| Company is offering 3.05 million common shares | 3.05 million | 82% |
| 6.09 million public-warrant shares linked to the pulled deal | 6.09 million | 165% |
| 6.10 million existing warrant shares left out of the deal | 6.10 million | 165% |
| Company aimed for $5.34 million in net proceeds | $5.34 million | 93% of March 31 cash |
The withdrawal gives the stock a boost, but only so much. The planned offering was set to add about $5.34 million to the balance sheet. As of March 31, Creative Medical held $5.72 million in cash. The filing said current cash plus expected proceeds would cover operating and capital costs at least into December 2027. But the same document made clear those funds would still fall short of taking any products through regulatory approval.
The rally has shifted the warrant math. According to the S-1/A, warrants from October 2025 cover up to 2.79 million shares at $2.86 each, exercisable for five years after shareholders approve on Dec. 26, 2025. CELZ last traded just under the strike, but earlier in the day it was above that mark.
The clinical setup isn’t fresh news. On June 22, Creative Medical said it got FDA clearance to expand its ADAPT study of CELZ-201 (Olastrocel) for chronic low back pain linked to degenerative disc disease. Creative Medical said the move adds a 15-patient group using under 90 mg per day of morphine equivalents, and that more than 85% of the group was already enrolled. An outside safety board gave the cohort a clean review, finding no major adverse events. CEO Warbington said the green light marked “another important step.” Nasdaq
In its withdrawal letter, the company said it asked the SEC to apply its filing fees to future registrations. No new financing was named.
